+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ovarian Cancer: Market Forecast Report 2019-2029

  • ID: 5019663
  • Report
  • April 2020
  • Region: Global
  • Black Swan Analysis

FEATURED COMPANIES

  • AstraZeneca
  • Roche
  • Tesaro

Forecast Overview

Over the 10-year forecast period for Ovarian Cancer (OC) from 2019 to 2029, we expect:

  • A total market growth from $1.1billion to $2.8billion
  • A major shift in treatment paradigms with the adoption of a diverse range of targeted therapies in a category where the broad standard of care for most patients has been platinum-based regimens.
  • Rapid adoption of PARPi and PD-1/PD-L1 targeting regimens and the emergence of first in class therapies (e.g. P53 activator APR-246, GAS-6i, tisotumab vedotin, oncolytic virus ONCOS-102 and cancer vaccine-DPX-Survivac).
  • Targeted therapies will drive longer treatment duration to deliver better treatment outcomes (evidenced in clinical trial results), offer better value and command premium pricing.
  • Roche will continue to dominate the market as the single largest player with approx. 31% of total market revenue in 2029 (down from 48% in 2019). Tecentriq (atezolizumab, PD-L1) gaining approval in OC in 2021 will offset some of the impact from loss of market protection on Avastin (bevacizumab) in 2019.
  • Generics to increase in total market revenue share from 18% to 25% by 2029 (driven by loss of exclusivity events).
  • Approximately 30% of the remaining market revenue will be generated by current OC drug manufacturers AstraZeneca, Tesaro and Clovis Pharmaceuticals, with the remaining share being generated by new market entrants such as Merck, Genmab and Aprea Therapeutics.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Roche
  • Tesaro

Forecast Overview

Disease Overview

  • Introduction
  • Classification of Ovarian Cancer
  • Histopathology and Therapy-Specific Disease Classification
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Patient & Clinical Management Guidelines (ESMO)
  • Patient & Clinical Management Flow developed for the forecast using NCCN and ESMO guidelines

Treatment Landscape -Overview

  • Molecules used in Ovarian Cancer Therapy
  • Regimens in Ovarian Cancer Therapy
  • Share of Patients Initiating Treatment per Line of Therapy

Market Forecast

  • Total Market Forecast
  • Market Forecast Revenue by Line of Therapy
  • Revenue Forecast by Patient Segments (BRCA vs Wild Type)
  • Patient Share Initiating Regimen per Line of Therapy
    • Adjuvant
    • First Line Metastatic
    • Second Line Platinum Sensitive
    • Second Line Platinum-Resistant
    • Maintenance Lines
  • Drug Class Market Positioning
    • Drug Class Market Shares by Lines of Therapy
  • Manufacturer MarketPositioning
    • Forecast Data
    • Forecast Commentary

Market Events

  • New Product Launches
  • Important New Product Launches
  • Loss of Market Protection

Appendix

  • List of Molecules used in Ovarian Cancer

Dynamic Patient Flow Methodology for Forecast

New Product Assumptions Methodology

Abbreviations Used in the Report

References

Other Services & Solutions

  • Reports & Publications
  • Online Epidemiology Databases
  • Online Pharmaceutical Pricing Database

List of Figures
Figure 1. The key drivers of ovarian market growth by 2029
Figure 2. OC incidence breakdown by FIGO staging 2019
Figure 3. OC patient treatment algorithm
Figure 4. Share of patients initiating treatment by line of therapy in 2019
Figure 5. Annual total market revenue 2019 vs 2029
Figure 6. Average duration of treatment by treatment setting 2019 vs 2029
Figure 7. Average cost of a patient month across all treatment settings
Figure 8. Average total cost per patient by line of therapy
Figure 9: Adjuvant regimen patient share split 2019 vs 2029
Figure 10. Adjuvant Maintenance regimen patient share split 2019 vs 2029
Figure 11. First line maintenance regimen patient share split 2019 vs 2029
Figure 12. Second line platinum resistant maintenance regimen patient share split 2019 vs 2029
Figure 13. Annual revenue by Drug Class of the total OC market
Figure 14. Total Adjuvant patient initiating share by drug class 2019 vs 2029
Figure 15. Total Adjuvant market revenue by drug class 2019 vs 2029
Figure 16. Total first line patient initiating share by drug class 2019 vs 2029
Figure 17. Total first line market revenue by drug class 2019 vs 2029
Figure 18. Total second line platinum sensitive patient initiating share by drug class 2019-2029
Figure 19. Total second line platinum sensitive market revenue by drug class 2019 vs 2029
Figure 20. Total second line platinum resistant patient initiating share by drug class 2019 vs 2029
Figure 21. Total second line platinum resistant market revenue by drug class 2019 vs 2029
Figure 22. Total maintenance lines patient initiating share by drug class 2019 vs 2029
Figure 23. Total maintenance lines market revenue by drug class 2019 vs 2029
Figure 24. Total OC revenue by manufacturer 2019 vs 2029

List of Tables
Table 1. PD-L1 expression in OC incidence population from 2019 to 2029
Table 2.Summary of molecules used or in trials to be used in OC therapy
Table 3. Summary of regimens used in each Wild Type OC setting
Table 4. Summary of regimens used in each BRCA 1/2 OC setting
Table 5. Market forecast 2019-2029
Table 6. Average cost of a patient month by line of therapy
Table 7. Incidence of OC in the USA (in 000s)
Table 8. Annual revenue by Line of Therapy ($MM)
Table 9. Annual total market revenue per therapy specific disease classification ($MM)
Table 10. Incidences of BRCA 1/2 or Wild Type mutations
Table 11. Total market revenue by major drug class ($MM)
Table 12. Total first line market revenue by major manufacturer ($MM)
Table 13. Total adjuvant market revenue by major manufacturer ($MM)
Table 14. Total platinum resistant market revenue by major manufacturer ($MM)
Table 15. Total platinum sensitive market revenue by major manufacturer ($MM)
Table 16. Total maintenance lines market revenue by major manufacturer ($MM)
Table 17. Launch dates and anticipated indicated line of therapy
Table 18. Loss of market protection dates within the forecast period
Table 19. Market totals
Table 20. Average treatment duration by line of therapy months
Table 21. Revenue per line of therapy ($MM)
Table 22. Total patient months per line of therapy
Table 23. Average monthly cost per line of therapy
Table 24. Revenue per therapy-specific disease classification ($MM)
Table 25. Patients initiating per Molecule for BRCA OC
Table 26. Patients initiating per molecule for Wild Type OC
Table 27. Total OC market revenue per drug class ($MM)
Table 28. Total OC market revenue by product manufacturer ($MM)
Table 29. Total OC market revenue by product ($MM)
Table 32. Products categorised by manufacturer
Table 33. Molecules categorised by drug class
Table 34. Abbreviations and acronyms used in the report

Note: Product cover images may vary from those shown

Loading
LOADING...

  • AstraZeneca
  • Roche    
  • Tesaro
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll